|
This complaint was reopened in reference to (b)(4).Manufacturing site evaluation: manufacturing and quality control data: the progav® was manufactured by a qualified employee in february 2016.Deviations during assembly did not occur.The valve was sterilized by miethke and released for shipment after final inspection.The progav® has a normal pressure range of 0 to 20 cmh2o.The valve was inspected as article fv441t.All parameters have been inspected and approved during the manufacturing process.All parameters have been assessed as meeting specification.Device examination: the valve was received submersed in an unidentified liquid in the provided returnkit.Visual inspection: no significant deformations or damage to the valve were detected during the visual inspection.This was confirmed through a measurement of the plane parallelism.Permeability test: a permeability test has shown that the valve is permeable.Adjustment test: the progav® was tested and is adjustable to all specified pressures.Braking force and brake function test: the brake functionality test has shown that the brake function is fully operational and the braking force is within the given tolerances.Computer controlled test: to investigate over/under-drainage, the opening pressure is measured using a miethke computer controlled testing apparatus which simulates a cerobrospinal fluid flow.The results showed that the valve operated within the accepted tolerance in the horizontal position.Result first, we performed a visual inspection of the progav®.No significant deformations or damage to the valve were detected during the visual inspection.This was confirmed through a measurement of the plane parallelism.Next, the permeability, adjustability, as well as the brake functionally and brake force, of the valve were tested.The valve operated as expected and met all specifications.Finally, the valve was dismantled.A small build-up of a substance (likely protein) was observed inside the valve.Based on the investigation, the claim of malfunction was not able to be substantiated.However, it is possible that the deposits observed inside the valve may have led to the malfunction.As described in scientific literature, the problem encountered is one of the known, inevitable risks of hydrocephalus (hc)-therapy by shunt implants.Manufacturing defects at the time of release have been excluded.The valve met all specifications of the final inspection when released from christoph miethke (b)(4).No further regulatory actions are required.
|